Indian scientists divided over restricted use approval for Covaxin
In a tweet on January 14, the Health Ministry said both Covishield and Covaxin approved for restricted use by the Indian regulator are safe. The Health Ministry released a statement…
Category: Clinical trial
Vaccine dilemma: To take or not to take Covaxin
True, in the U.S., vaccines from both Pfizer and Moderna are available and recipients, who are health-care workers and nursing home residents, have no option to choose the vaccine. In…
Serious violations in Covaxin trial in Bhopal show nothing has changed since the egregious HPV vaccine trial
The phase-3 clinical trial of Bharat Biotech’s COVID-19 vaccine, Covaxin, by a private hospital in the Bhopal-based Peoples College of Medical Sciences & Research Centre appears to suffer from serious…
New challenges in conducting COVID-19 vaccine trials in India
The Ahmedabad-based Zydus Cadilla only recently got the regulatory permission to carry out phase-3 trial and has to begin the recruitment, while the Hyderabad-based Biological E is yet to reach…
I would not take Covaxin without efficacy data: Gagandeep Kang
Scientists, manufacturers and drug regulators have been speeding up the timelines to develop, test and approve vaccines for emergency use. Three safe and efficacious vaccines from Pfizer, Moderna and AstraZeneca…
With hasty approval, India squanders an opportunity to build trust in COVID-19 vaccine
Transparency in the approval process is vital for gaining the trust of people so that they don’t hesitate to take the vaccine. If there is already some degree of anxiety…
Why people with prior SARS-CoV-2 infection still need to be vaccinated
Since vaccine shortage is expected to last at least for a few months, it may seem appealing to delay or avoid vaccinating those who have been naturally infected. But does…
UK uses an untested strategy to rapidly but partially protect people at risk
With the virus running amok in the country and vaccines in short-supply, the U.K. is attempting an untested strategy of delaying the second dose of both AstraZeneca and Pfizer vaccine even in the absence of data from large trials. The intent is to rapidly but partially protect more individuals who are at risk.
